Abstract
To provide a comprehensive evaluation of the economic burden of major depressive disorder (MDD) in the United States (US) in 2019 and estimate the early impact that the COVID-19 pandemic in 2020 may have had on the overall disease burden.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
